Sarogni, Patrizia (2017) EGFR activation promotes a hypertrophic phenotype in NAGLU depleted cardiomyoblasts, depicting features of mucopolysaccharidosis IIIB. [Tesi di dottorato]

[img]
Preview
Text
sarogni_patrizia_30.pdf

Download (4MB) | Preview
[error in script] [error in script]
Item Type: Tesi di dottorato
Lingua: English
Title: EGFR activation promotes a hypertrophic phenotype in NAGLU depleted cardiomyoblasts, depicting features of mucopolysaccharidosis IIIB
Creators:
CreatorsEmail
Sarogni, Patriziapatrizia.sarogni@unina.it
Date: 11 December 2017
Number of Pages: 59
Institution: Università degli Studi di Napoli Federico II
Department: dep14
Dottorato: phd054
Ciclo di dottorato: 30
Coordinatore del Corso di dottorato:
nomeemail
Avvedimento, Vittorio Enricoavvedim@unina.it
Tutor:
nomeemail
Pavone, Luigi MicheleUNSPECIFIED
Date: 11 December 2017
Number of Pages: 59
Uncontrolled Keywords: Mucopolysaccharidosis IIIB; NAGLU; Hypertrophy; Lysosomes
Settori scientifico-disciplinari del MIUR: Area 05 - Scienze biologiche > BIO/10 - Biochimica
Date Deposited: 27 Dec 2017 23:37
Last Modified: 20 Mar 2019 09:51
URI: http://www.fedoa.unina.it/id/eprint/12189

Abstract

Mucopolysaccharidosis (MPS) IIIB is a lysosomal storage disease due to the deficiency of the enzyme α-N-acetylglucosaminidase (NAGLU) required for heparan sulfate degradation. Since perturbation of lysosomal homeostasis represents an important cause of cardiomyocyte dysfunction in cardiovascular diseases, we generated a model of the MPS IIIB by silencing NAGLU gene expression in H9C2 rat cardiomyoblasts. NAGLU-depleted H9C2 exhibited accumulation of abnormal lysosomes and a hypertrophic phenotype. Through a phospho-receptor tyrosine kinase array, we found the specific activation of the epidermal growth factor receptor (EGFR) in NAGLU-depleted H9C2 compared to control cells. The pretreatment of NAGLU-depleted H9C2 with the specific EGFR inhibitor AG1478 caused the reduction of both lysosomal aberration and cellular hypertrophy. Similar results were obtained when NAGLU-depleted H9C2 were treated with PD98059, a selective inhibitor of MEK/ERK downstream targets of EGFR. Furthermore, we found increased phosphorylation levels of c-Src in NAGLU-depleted H9C2 where c-Src perturbation affected the hypertrophic response. However, c-Src phosphorylation remained unaffected after treatment of NAGLU-depleted H9C2 clones with AG1478, posing c-Src phosphorylation upstream EGFR activation. Finally, the heparin-binding EGF-like growth factor (HB-EGF) protein resulted to be up-regulated in NAGLU-depleted H9C2, and its silencing caused a reduction of the hypertrophic response. These results demonstrate that both c-Src and HB-EGF may contribute to the hypertrophic phenotype of NAGLU-depleted cardiomyoblasts by activating EGFR signaling, and suggest that the inhibition of EGFR pathway might represent an effective therapeutic strategy for the cure of MPS IIIB cardiac disease.

Actions (login required)

View Item View Item